Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

[Gastrointestinal and pancreatic neuroendocrine tumors: a clinicopathologic and immunohistochemical study].

Sun LM, Qiu XS, Wang EH.

Zhonghua Bing Li Xue Za Zhi. 2012 Oct;41(10):696-7. doi: 10.3760/cma.j.issn.0529-5807.2012.10.011. Chinese. No abstract available.

PMID:
23302313
2.

[Chinese pathologic consensus for standard diagnosis of gastrointestinal and pancreatic neuroendocrine neoplasm].

Chinese Pathologic Consensus Group for Gastrointestinal and Pancreatic Neuroendocrine Neoplasm.

Zhonghua Bing Li Xue Za Zhi. 2011 Apr;40(4):257-62. Chinese. No abstract available.

PMID:
21616002
3.

[Standardization in pathologic diagnosis of gastrointestinal and pancreatic neuroendocrine tumors].

Zheng J.

Zhonghua Bing Li Xue Za Zhi. 2010 Dec;39(12):793-5. Chinese. No abstract available.

PMID:
21215092
4.

P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters.

Kımıloğlu Şahan E, Erdoğan N, Ulusoy İ, Samet E, Akyıldız İğdem A, Gönüllü D.

Turk J Gastroenterol. 2015 Mar;26(2):104-11. doi: 10.5152/tjg.2015.1965.

5.

[Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].

Yao W, Wang W, Li G.

Zhonghua Zhong Liu Za Zhi. 2014 Apr;36(4):287-93. Chinese.

PMID:
24989916
6.

[Neuroendocrine neoplasm of digestive system with different grades: a clinicopathologic and prognostic study].

Zhang MH, Liu YH, Luo XL, Lin XT, Zhuang HG.

Zhonghua Bing Li Xue Za Zhi. 2012 Jul;41(7):448-51. doi: 10.3760/cma.j.issn.0529-5807.2012.07.004. Chinese.

PMID:
22932454
7.

NESP55, a novel chromogranin-like peptide, is expressed in endocrine tumours of the pancreas and adrenal medulla but not in ileal carcinoids.

Jakobsen AM, Ahlman H, Kölby L, Abrahamsson J, Fischer-Colbrie R, Nilsson O.

Br J Cancer. 2003 Jun 2;88(11):1746-54.

8.

Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.

Ezziddin S, Adler L, Sabet A, Pöppel TD, Grabellus F, Yüce A, Fischer HP, Simon B, Höller T, Biersack HJ, Nagarajah J.

J Nucl Med. 2014 Aug;55(8):1260-6. doi: 10.2967/jnumed.114.137166. Epub 2014 May 29.

9.

High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.

Knösel T, Chen Y, Altendorf-Hofmann A, Danielczok C, Freesmeyer M, Settmacher U, Wurst C, Schulz S, Yang LL, Petersen I.

J Cancer Res Clin Oncol. 2012 Mar;138(3):397-403. doi: 10.1007/s00432-011-1107-9. Epub 2011 Dec 8.

PMID:
22160160
10.

[Standardization in diagnosis of gastrointestinal and pancreatic neuroendocrine neoplasms: the Chinese consensus].

Chinese pathologic consensus group for gastrointestinal and pancreatic neuroendocrine neoplasms.

Zhonghua Bing Li Xue Za Zhi. 2013 Oct;42(10):691-4. Chinese. No abstract available.

PMID:
24439254
11.

Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system.

Delektorskaya VV, Kozlov NA, Chemeris GY.

Klin Lab Diagn. 2013 Oct;(10):48-50, 10-3. English, Russian.

PMID:
24640093
12.

Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.

Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Prasad V, Kulkarni H, Haugvik SP, Hommann M, Baum RP.

Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1659-68. doi: 10.1007/s00259-011-1846-5. Epub 2011 May 31.

PMID:
21626438
13.

Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.

Ozkara S, Aker F, Yesil A, Senates E, Canbey C, Yitik A, Gonen C.

Hepatogastroenterology. 2013 Oct;60(127):1665-72.

PMID:
24627925
14.

Role of resection of the primary pancreatic neuroendocrine tumor in the multidisciplinary treatment of patients with unresectable synchronous liver metastases: a case series.

Kondo NI, Ikeda Y, Maehara S, Sugimoto R, Nishiyama K, Sakaguchi Y.

JOP. 2013 Jul 10;14(4):415-22. doi: 10.6092/1590-8577/1291.

15.

[Neuroendocrine tumors of pancreas (clinicomorphological, immunohistochemical and electron microscopic study)].

Kazantseva IA, Gurevich LE, Kalinin AP, Borodataia EV, Kuzin NM, Egorov AV, Bronshteĭn MI.

Arkh Patol. 1999 Nov-Dec;61(6):32-8. Russian.

PMID:
10664818
16.

Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.

Kaemmerer D, Träger T, Hoffmeister M, Sipos B, Hommann M, Sänger J, Schulz S, Lupp A.

Oncotarget. 2015 Sep 29;6(29):27566-79. doi: 10.18632/oncotarget.4491.

17.
18.

[Clinicopathological features of colorectal neuroendocrine neoplasms and prognostic significance of WHO staging system].

Zhang XH, Lu XL, Wu N, Liu B, Wang FY, Zhang RS, Zhou XJ.

Zhonghua Bing Li Xue Za Zhi. 2013 Mar;42(3):191-6. doi: 10.3760/cma.j.issn.0529-5807.2013.03.011. Chinese.

PMID:
23769440
19.

Neuroendocrine markers expression in pancreatic serous cystadenoma.

Kanehira K, Khoury T.

Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):141-6. doi: 10.1097/PAI.0b013e3181f5023d.

PMID:
21030861
20.

Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics?

Rebours V, Cordova J, Couvelard A, Fabre M, Palazzo L, Vullierme MP, Hentic O, Sauvanet A, Aubert A, Bedossa P, Ruszniewski P.

Dig Liver Dis. 2015 Nov;47(11):973-7. doi: 10.1016/j.dld.2015.06.005. Epub 2015 Jun 20.

PMID:
26169284
Items per page

Supplemental Content

Write to the Help Desk